Primary Care Medicines Formulary - GP Ref · primary care and so not all may be specifically mentioned. Clinicians can and should prescribe medicines approved by NICE TAs where patients

Primary Care

Medicines

Formulary

June 2016

1

Scope of this formulary

The aim of this formulary is to promote safe, effective and affordable first choice prescribing, when initiated within a primary care setting within Bedfordshire Clinical Commissioning Group (BCCG). It does not cover specialist drugs initiated in secondary or tertiary care. Policies and shared care arrangements for these drugs can be found within the Joint Prescribing Committee (JPC) section of the BCCG website Recommendations are also included in the ScriptSwitch® profile where appropriate.

The formulary is not intended to supersede NICE Technology Appraisals (TAs). Not all NICE approved drugs are appropriate for general initiation in primary care and so not all may be specifically mentioned. Clinicians can and should prescribe medicines approved by NICE TAs where patients meet the clinical criteria set in the guidance and where it is the most appropriate treatment option in the clinical judgement of the treating clinician.

The process for amendments to this formulary is set out on the BCCG website. The current version of this formulary will be available on the BCCG website.

2

Before changing a medicine check patients’ adherence to their existing prescribed medication –

Can they take their medicines? Do they take their medicines?

BNF Section Preparations Comments

1: GASTRO-INTESTINAL SYSTEM

1.1 Dyspepsia and gastro-oesophageal reflux disease

1st choice Peptac® sugar free suspension aniseed/peppermint 500ml 2nd choice low sodium option Gaviscon® Advance sugar free suspension aniseed/peppermint 500ml

6.2mmol Na+/10ml. Dose 10-20ml. Pack size 500ml 4.6mmol Na+ 2mmol K+ / 10ml. Dose 5-10ml. Pack size 250ml or 500ml

1.2 Antispasmodics & other drugs altering gut motility

Hyoscine butylbromide tablets 10mg Mebeverine tablets 135mg Peppermint oil 0.2ml gastro resistant capsules

NB not modified release

1.3.1 H2-receptor antagonists Ranitidine tablets 150mg & 300mg

1.3.5 Proton pump inhibitors Lansoprazole gastro resistant capsules 15mg & 30mg Omeprazole gastro resistant capsules 10mg & 20mg Pantoprazole gastro resistant tablets 20mg & 40mg

1.4 Acute diarrhoea Loperamide capsules 2mg

1.5 Chronic bowel disorders Octasa® (mesalazine modified release) tablets 400mg & 800mg tablets Pentasa® (mesalazine modified release) tablets 500mg & 1000mg Salazopyrin EN® tablets (sulphasalazine enteric coated ) 500mg

3


1.6.1 Bulk-forming laxatives Ispaghula husk 3.5g effervescent granules, gluten free, sugar free (Fybogel®)

Low Na+

1.6.2 Stimulant laxatives Senna tablets 7.5mg & sugar free oral solution 7.5mg/ 5ml

1.6.4 Osmotic laxatives Lactulose solution 500ml Cosmocol® lemon and lime sachets Cosmocol® orange sachets Cosmocol® plain sachets Cosmocol Half® 6.9g sachets Cosmocol Paediatric® 6.9g sachets

Cosmocol® range contains macrogol ‘3350’

1.7 Local preparations for anal and rectal disorders

Uniroid HC® ointment & suppositories Xyloproct® ointment

Anusol® cream, ointment & suppositories Anusol HC® ointment & suppositories These products are Pharmacy OTC items and should be purchased.

2: CARDIOVASCULAR SYSTEM

2.1 Positive inotropic drugs Digoxin tablets 62.5mcg, 125mcg & 250mcg

2.2.1 Thiazides and related diuretics

Indapamide tablets 2.5mg

NICE Clinical Guideline 127 Hypertension

2.2.2 Loop diuretics Furosemide tablets 20mg & 40mg

2.2.3 Potassium-sparing diuretics and aldosterone antagonists

Spironolactone tablets 25mg & 50mg

4


2.4 Beta-adrenoceptor blocking drugs

Atenolol tablets 25mg, 50mg & 100mg Bisoprolol tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg & 10mg Propranolol tablets 10mg & 40mg Propranolol modified release capsules 80mg & 160mg

Also used for migraine prophylaxis

2.5.4 Alpha-adrenoceptor blocking drugs

Doxazosin tablets 1mg, 2mg & 4mg NB Not modified release

2.5.5.1 Angiotensin-converting enzyme inhibitors

Lisinopril tablets 2.5mg, 5mg, 10mg & 20mg Perindopril erbumine tablets 2mg, 4mg & 8mg Ramipril capsules 1.25mg, 2.5mg, 5mg & 10mg

NB not arginine

2.5.5.2 Angiotensin-II receptor antagonists

Candesartan tablets 4mg, 8mg, 16mg & 32mg Losartan tablets 25mg, 50mg & 100mg

2.6.1 Nitrates

Glyceryl trinitrate pump/aerosol spray 400mcg, 180dose Chemydur® (Isosorbide mononitrate MR) tablets 60mg

2.6.2 Calcium-channel blockers Diltiazem longer acting formulations

Amlodipine tablets 5mg and 10mg Tildiem MR® tabs 60mg Viazem XL® capsules 120mg, 180mg, 240mg, 300mg & 360mg. Angitil SR® capsules 90mg, 120mg & 180mg

Three times a day dose Once daily dose Twice daily dose

2.6.3 Other anti-anginal dugs Nicorandil tablets 10mg & 20mg

2.8 Anticoagulants and protamine

Warfarin tablets 500mcg, 1mg, 3mg & 5mg

Refer to Cardiac Network Guidance

2.9 Antiplatelet drugs Aspirin dispersible tablets 75mg Clopidogrel tablets 75mg

5

BNF Section

Preparations Comments

2.11 Antifibrinolytic drugs and haemostatics

Tranexamic acid tablets 500mg

2.12 Lipid-regulating drugs Simvastatin tablets 10mg, 20mg & 40mg Atorvastatin tablets 10mg, 20mg, 40mg & 80mg Pravastatin tablets 10mg, 20mg & 40mg

3: RESPIRATORY SYSTEM

3.1.1.1 Selective beta2 agonists Short acting Salbutamol 100mcg/dose inhaler CFC free Longer acting Easyhaler formoterol 12mcg/dose

3.1.2 Antimuscarinic bronchodilators

Ipratropium bromide 20mcg/dose inhaler CFC free Tiotropium bromide 18mcg inhalation powder, hard capsule Tiotropium Respimat® 2.5 mcg inhalation solution

3.1.3 Theophylline Phyllocontin Continus® tablets 225mg

3.1.4 Compound bronchodilator preparations

Tiotropium / Olodaterol 2.5 mcg / 2.5 mcg inhalation solution (Spiolto Respimat®) Aclidinium / Formoterol (Duaklir Genuair®) 340 mcg /12 mcg inhalation powder

COPD in adults only

6


3.2 Corticosteroids Compound preparations

Clenil Modulite® cfc-free aerosol inhaler beclometasone dipropionate (BDP) 50, 100, 200 & 250 mcg per dose Asthma Fostair® cfc free inhaler 100/6 and 200/6 (beclometasone dipropionate 100mcg or 200mcg /formoterol fumarate dihydrate 6mcg) Fostair Nexthaler® 100/6 and 200/6

(beclometasone dipropionate 100mcg or 200mcg / formoterol fumarate dihydrate 6mcg dry powder inhaler) DuoResp Spiromax®

(budesonide 160mcg/formoterol fumarate dihydrate 4.5mcg dry powder inhaler (equivalent to a metered dose of 200mcg budesonide and 6mcg formoterol fumarate dihydrate)) DuoResp Spiromax® budesonide 320mcg formoterol fumarate dihydrate 9mcg dry powder inhaler (equivalent to a metered dose of 400mcg budesonide and 12mcg formoterol fumarate dihydrate) Symbicort Turbohaler® budesonide 100mcg/formoterol fumarate dihydrate 6mcg

Symbicort Turbohaler® budesonide 200mcg/formoterol fumarate dihydrate 6mcg

Adult use. 18 years + NB Fostair® cfc-free inhaler has extra fine particles and has 5 months shelf life once dispensed (100mcg extra-fine beclometasone dipropionate is equivalent to 250mcg cfc-free beclometasone dipropionate) Adult use. 18 years + Use within 6 months of first opening the pouch Adult use. 18 years + Use within 6 months of first opening the foil wrap Adult use. 18 years + Use within 6 months of first opening the foil wrap Child 6-12 years Shelf life 2 years Child 12-17 years Shelf life 2 years

7


Compound preparations

COPD Fostair® cfc-free inhaler 100/ 6 (beclometasone dipropionate 100mcg/ formoterol fumarate dihydrate 6mcg) Fostair Nexthaler® 100/ 6

(beclometasone dipropionate 100mcg/ formoterol fumarate dihydrate 6mcg dry powder inhaler) Symbicort turbohaler® budesonide 400 mcg/ formoterol fumarate dihydrate 12mcg DuoResp Spiromax® budesonide 160mcg/ formoterol fumarate dihydrate 4.5mcg dry powder inhaler (equivalent to a metered dose of 200mcg budesonide and 6mcg formoterol fumarate dihydrate) DuoResp Spiromax® budesonide 320mcg/ formoterol fumarate dihydrate 9mcg dry powder inhaler (equivalent to a metered dose of 400mcg budesonide and 12mcg formoterol fumarate dihydrate)

NB Fostair® cfc-free inhaler has extra fine particles and has 5 months shelf life when dispensed (100mcg extra-fine beclometasone dipropionate is equivalent to 250mcg cfc-free beclometasone dipropionate) Shelf life 2 years Use within 6 months of first opening the foil wrap Use within 6 months of first opening the foil wrap

3.3.2 Leukotriene receptor antagonists

Montelukast tablets 10mg Montelukast chewable tablets sugar free 4mg & 5mg

3.4 Antihistamines, hyposensitisation, and allergic emergencies

Cetirizine tablets 10mg Chlorphenamine tablets 4mg Loratadine tablets 10mg

4: CENTRAL NERVOUS SYSTEM

4.1 Hypnotics and anxiolytics Diazepam tablets 2mg & 5mg Zopiclone tablets 3.75mg & 7.5mg

short term use – up to 4 weeks

8


4.2 Drugs used in psychoses and related disorders

Chlorpromazine tablets 25mg, 50mg & 100mg Haloperidol capsules 500mcg Haloperidol tablets 1.5mg & 5mg. Risperidone tablets 500mcg, 1mg, 2mg, 3mg & 4mg

Olanzapine and Quetiapine initiated by Secondary Care

4.3.1 Tricyclic and related antidepressant drugs

Amitriptyline tablets 10mg, 25mg & 50mg

4.3.3 Selective serotonin re-uptake inhibitors

Fluoxetine capsules 20mg Sertraline tablets 50mg & 100mg Citalopram tablets 10mg, 20mg & 40mg

4.3.4 Other antidepressant drugs

Venlafaxine tablets 37.5mg & 75mg Vensir® XL capsules 75mg & 150mg

Twice a day dose Once a day dose NB Regular BP monitoring required.

4.4 CNS stimulants & drugs used for attention deficit hyperactivity disorder

Initiated by Secondary Care

4.5 Drugs used in the treatment of obesity

Orlistat capsules 120mg

TA22 replaced by Clinical Guideline 43 Obesity - for appropriate use and monitoring

4.6 Drugs used in nausea and vertigo

Betahistine tablets 8mg & 16mg Domperidone tablets 10mg Prochlorperazine tablets 5mg and buccal tablets 3mg

4.7.1 Non-opioid analgesics and compound analgesic preparations

Paracetamol tablets 500mg Paracetamol sugar free suspension 120mg/5ml & 250mg/5ml Zapain® (co-codamol 30mg/500mg)

tablets/caplets ◪

◪ = BNF - less suitable for prescribing

9


4.7.2 Opioid analgesics Codeine phosphate tablets 30mg Morphine sulphate oral solution 10mg in 5ml Zomorph® capsules 10mg, 30mg, 60mg, 100mg & 200mg Fencino® (fentanyl) patches 12, 25, 50, 75 & 100 mcg/hour Matrifen® (fentanyl) patches 12, 25, 50, 75 & 100 mcg/hour Tramadol capsules 50mg

4.7.4.1 Treatment of acute migraine

Naratriptan tablets 2.5mg Sumatriptan tablets 50mg & 100mg Zolmitriptan tablets 2.5mg Zolmitriptan orodispersible sugar free tablets 2.5mg

NB not 5mg strength

4.7.4.2 Prophylaxis of migraine

See propranolol 2.4

4.8 Antiepileptic drugs Carbamazepine tablets 100mg, 200mg & 400mg Gabapentin 100mg, 300mg & 400mg capsules Tegretol® prolonged release (carbamazepine modified release) tablets 200mg & 400mg

MHRA advise prescribe by brand (Tegretol®) Recommendations only apply to management of neuropathic pain. Epilepsy patients are managed in Secondary Care

4.9 Drugs used in parkinsonism and related disorders


4.10.2 Nicotine dependence

Smoking cessation products are the financial responsibility of Public Health if the patient is referred into the stop smoking service. NRT, bupropion and varenicline are equal first choices in smoking cessation

10

BNF Section

Preparations Comments

5: INFECTIONS Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines

5.1.1.1 Benzylpenicillin and phenoxymethylpenicillin

Phenoxymethylpenicillin tablets 250mg Phenoxymethylpenicillin sugar free oral solution 125mg/5ml and 250mg/5ml

5.1.1.2 Penicillinase-resistant penicillins

Flucloxacillin capsules 250mg & 500mg Flucloxacillin oral solution 125mg/5ml & 250mg/5ml

5.1.1.3 Broad-spectrum penicillins

Amoxicillin capsules 250mg & 500mg Amoxicillin sugar free suspension 125mg/5ml & 250mg/5ml Co-amoxiclav tablets 250mg/125mg & 500mg/125mg

5.1.3 Tetracyclines Doxycycline capsules 50mg & 100mg Oxytetracycline tablets 250mg Lymecycline capsules 408mg

2nd line to oxytetracycline

5.1.5 Macrolides Clarithromycin tablets 250mg & 500mg Clarithromycin suspension 125mg/5ml and 250mg/5ml Erythromycin gastro resistant tablets 250mg Erythromycin ethylsuccinate sugar free suspension 125mg/5ml & 250mg/5ml

NB Not modified release

5.1.8 Sulphonamides and trimethoprim

Trimethoprim tablets 100mg & 200mg Trimethoprim sugar free suspension 50mg/5ml

11


5.1.11 Metronidazole and tinidazole

Metronidazole tablets 200mg & 400mg

5.1.13 Urinary-tract infections

Nitrofurantoin tablets 50mg & 100mg Nitrofurantoin modified release capsules 100mg

5.2 Antifungal drugs Fluconazole capsules 150mg Terbinafine tablets 250mg

5.3 Antiviral drugs Aciclovir tablets 200mg, 400mg & 800mg

5.5 Anthelmintics Mebendazole suspension 100mg in 5ml Mebendazole chewable sugar free tablets 100mg

Licensed use in child over 2 years Unlicensed use in child under 2 years – see BNFc

6: ENDOCRINE SYSTEM

6.1.1 Insulins Insulin (all forms)

Prescribe by brand name

6.1.1.3 Hypodermic equipment

Mylife® Penfine Classic needles 4mm/32 gauge & 6mm/32 gauge GlucoRx® Finepoint pen needles 4mm/31 gauge, 5mm/31 gauge & 6mm/31 gauge

Listed under Appliances, Hypodermic Equipment in Part IXA of the Drug Tariff

6.1.2.1 Sulphonylureas Gliclazide tablets 80mg


6.1.2.2 Biguanides Metformin tablets 500mg & 850mg


6.1.6 Diagnostic and monitoring devices for diabetes mellitus

MyLife Pura® test strips TRUEresult® blood glucose test strips

6.2 Thyroid and antithyroid drugs

Carbimazole tablets 5mg & 20mg Levothyroxine sodium tablets 25mcg, 50mcg & 100mcg

6.3 Corticosteroids Prednisolone tablets 1mg & 5mg Prednisolone Dompe® 1mg/1ml oral solution

NB Not enteric coated

12


6.4.1.1 Oestrogens and HRT Elleste-Duet® tablets 1mg & 2mg Elleste -Solo® tablets 1mg & 2mg Evorel® 25, 50, 75 & 100 patches Premique® low dose tablets PrempakC® tablets 0.625mg & 1.25mg

6.4.2 Male sex hormones and antagonists

Finasteride tablets 5mg

6.6 Drugs affecting bone metabolism

Alendronic acid 70mg tablets Risedronate tablets 35mg

Weekly dosage - Not licensed for use in men. Weekly dosage

7: OBSTETRICS, GYNAECOLOGY, AND URINARY-TRACT DISORDERS

7.2 Treatment of vaginal and vulval conditions

Clotrimazole pessaries 500mg Estriol cream 0.01% with applicator Estradiol (Vagifem®) pessaries 10mcg

Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines In Preganancy 100mg at night x 6 nights

7.3.1 Combined hormonal contraceptives Emergency contraception

Low strength: Loestrin 20® tablets Sunya 20/75® tablets Standard strength: Microgynon 30® tablets Ovranette® tablets Lizinna® Tablets Levonorgestrel 1.5mg tablets

13

BNF Section Preparations

Preparations

7.3.2.1 Oral progestogen-only contraceptives

Cerelle® tablets Micronor® (norethisterone) tablets 350mcg

For women who cannot tolerate oestrogen containing contraceptives or in whom such preparations are contraindicated

7.3.2.2 Parenteral progestogen-only contraceptives

Medroxyprogesterone 150mg/1ml suspension for injection pre filled syringe

7.3.2.3 Intra-uterine progestogen-only device

Mirena® 20mcg/24hours intrauterine device

7.4.1 Drugs for urinary retention

Tamsulosin MR capsules 400mcg

NB not tablets

7.4.2 Drugs for urinary frequency, enuresis and incontinence

1st choice Oxybutynin tablets 2.5mg and 5mg 2nd choice Tolterodine tablets 1mg & 2mg Tolterodine modified release capsules 4mg Neditol XL® Solifenacin tablets 5mg & 10mg

3rd choice

7.4.5 Drugs for erectile dysfunction

Sildenafil tablets 25mg, 50mg & 100mg

8: MALIGNANT DISEASE & IMMUNOSUPPRESSION

8.2 Drugs affecting the immune response


8.3 Sex hormones and hormone antagonists in malignant disease


9: NUTRITION AND BLOOD

9.1 Anaemias and some other blood disorders

Ferrous fumarate tablets 210mg Folic acid tablets 5mg Hydroxocobalamin injection 1mg (1000mcg) in 1ml

14

BNF Section Preparations

Preparations

9.2 Fluids and electrolytes Dioralyte® sachets (all flavours) x 20

9.4 Enteral Nutrition

Food fortification is 1st line, choice should be dietitian lead

Ensure you have weight, BMI and MUST score before prescribing

9.5 Minerals See 9.6. for calcium with vitamin D

9.6 Vitamins Accrete D3® tablets TheiCal D3® tablets chewable Calfovit D3 ® sachets

1.0 - 1.2g Calcium + 800iu Vit D per day recommended for the prophylaxis of osteoporosis in elderly housebound patients in Bedfordshire

One tablet twice a day Vit D 10mcg (400units) & calcium 600mg One tablet once a day Vit D 22mcg (880units) & calcium 1000mg One sachet once a day Vit D 20mcg (800units) & calcium 1.2g

10: MUSCULOSKELETAL AND JOINT DISEASES

10.1.1 Non-steroidal anti-inflammatory drugs

Ibuprofen tablets 200mg, 400mg & 600mg tablets Naproxen tablets 250mg & 500mg Mefenamic acid tablets 500mg

For dysmenorrhoea

10.1.2.2 Local corticosteroid injections

Methylprednisolone 40mg with lidocaine 10mg/1ml injection 1ml vial Methylprednisolone 80mg with lidocaine 10mg/1ml injection 2ml vial

15


10.1.3 Drugs that suppress the rheumatic disease process

Methotrexate tablets 2.5mg and s/c injections- see shared care guidance


10.1.4 Gout and cytotoxic-induced hyperuricaemia

Allopurinol tablets 100mg & 300mg Colchicine tablets 500 mcg

Prophylaxis Acute attack

10.2 Drugs used in neuromuscular disorders

Baclofen tablets 10mg

10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief

Ibuprofen 5% gel 50g & 100g Fenbid®

11: EYE

11.3 Anti-infective eye preparations

Chloramphenicol eye drops 0.5% Chloramphenicol eye ointment 1%

Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines

11.4 Corticosteroids and other anti-inflammatory preparations

Sodium cromoglicate eye drops 2%

11.8 Miscellaneous ophthalmic preparations

Clinitas carbomer eye Gel® 0.2% Hypromellose eye drops 0.3%

Tear-Lac® - if preservative free required

12: EAR, NOSE, AND OROPHARYNX

12.1 Drugs acting on the ear Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines

12.2 Drugs acting on the nose 1st choice Beconase® (beclometasone) aqueous nasal spray 200 dose 2nd choice Fluticasone furoate (Avamys®) nasal spray 120dose Naseptin® cream 15g

16


12.3 Drugs acting on the oropharynx

Benzydamine sugar free mouthwash 0.15% 300ml Nystan® (nystatin) suspension 100,000 units in 1ml

13: SKIN

13.2 Emollient and barrier preparations

Percentage of Paraffin in brackets:

Cetraben® emollient cream (23.7%) Zerobase® emollient cream (21%) Zerocream® cream (27%) Zeroguent®cream (15%) ZeroAQS® cream (21%) Zerodouble® gel (30%) Zeroderm® Ointment (70%) Zerolatum® emollient bath (60%)

Safety Alert Paraffin-based products are HIGHLY FLAMMABLE. These products and items with their residue ( clothes and/ or bed clothes) should NEVER be placed near an open flame, including lighted cigarettes and other smoking equipment

13.4 Topical corticosteroids Betamethasone valerate cream and ointment 0.025% (Betnovate-RD®) Betamethasone valerate cream & ointment 0.1% Betamethasone valerate 0.1% scalp application (Betnovate® ) Clobetasone butyrate cream and ointment 0.05% (Eumovate® ) Hydrocortisone cream and ointment 0.5% & 1% Combination products Hydrocortisone 1% + miconazole nitrate 2% cream (Daktacort® ) Betamethasone valerate 0.1% + fusidic acid 2% cream (Fucibet® ) Hydrocortisone acetate 1% + fusidic acid 2% cream

13.5 Preparations for eczema and psoriasis

Calcipotriol ointment 50mcg/g Calcipotriol scalp solution 50mcg/ml

17

13.6 Acne and rosacea Adapelene cream/ gel 0.1% Clindamycin aqueous lotion/ alcoholic solution 1% Co-cyprindiol tablets 2000mcg/35mcg Erythromycin 40mg/ml +Zinc acetate 12mg/ml lotion (Zineryt®)


13.7 Preparations for warts and calluses

Salatac® gel These products are Pharmacy OTC items and should be purchased.

13.9 Shampoos and other preparations for scalp and hair conditions

Ketoconazole shampoo 2%

13.10 Anti-infective skin preparations

Aciclovir cream 5% Clotrimazole cream 1% Fusidic acid cream 2% Rozex® cream & gel (metronidazole 0.75%)

Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines

15: ANAESTHESIA

15.2 Local anaesthesia Lidocaine injection 1% - 2ml, 5ml, 10ml & 20ml Lidocaine injection 2% - 2ml, 5ml & 20ml

18

The following NICE published Technology Appraisals are included within this formulary in accordance with the clinical criteria set out within each guidance and subject to the clinical judgement of the treating clinician. Not all of these will be appropriate for routine initiation, or continuation of, prescribing by a GP.

Ref Title Date Issued

TA10 Asthma (children under 5) - inhaler devices Aug 2000

TA38 Asthma (older children) - inhaler devices Mar 2002

TA77 Insomnia - newer hypnotic drugs Apr 2004

TA81 Atopic dermatitis (eczema) - topical steroids Aug 2004

TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus Aug 2004

TA98 Methylphenidate, atomoxetine & dexamfetamine for ADHD in children & adolescents Mar 2006

TA114 Drug misuse - methadone & buprenorphine Jan 2007

TA115 Drug misuse - naltrexone Jan 2007

TA123 Smoking cessation - varenicline July 2007

TA131 Asthma (in children) - corticosteroids Nov 2007

TA134 Psoriasis - infliximab Jan 2008

TA138 Asthma (in adults) - corticosteroids Mar 2008

TA146 Psoriasis - adalimumab Jun 2008

TA151 Diabetes - insulin pump therapy July 2008

TA157 Venous thromboembolism - dabigatran Sep 2008

TA158 Influenza (prophylaxis) - amantadine, oseltamivir & zanamivir Sep 2008

TA160 Osteoporosis - primary prevention Jan 2011

TA161 Osteoporosis - secondary prevention including strontium ranelate Jan 2011

TA163 Ulcerative colitis (acute exacerbations) - infliximab Dec 2008

TA168 Influenza - zanamivir, amantadine and oseltamivir Feb 2009

TA170 Venous thromboembolism - rivaroxaban Apr 2009

TA177 Treatment of severe chronic hand eczema - alitretinoin Aug 2009

TA180 Psoriasis - ustekinumab Sep 2009

TA187 Infliximab and adalimumab for the treatment of Crohn's disease May 2010

TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 2010

TA197 Atrial fibrillation - dronedarone (re-issued) Dec 2012

TA199 Psoriatic arthritis - etanercept, infliximab & adalimumab Aug 2010

TA204 Osteoporotic fractures - denosumab Oct 2010

TA210 Vascular disease - clopidogrel and dipyridamole Dec 2010

TA211 Constipation (women) - prucalopride Dec 2010

TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Jan 2011

TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine Mar 2011

TA220 Psoriatic arthritis - golimumab Apr 2011

TA221 Romiplostim for chronic immune idiopathic thrombocytopenic purpura (ITP) Apr 2011

TA223 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate

May 2011

http://www.nice.org.uk/guidance/ta/published/index.jsp?d-16544-s=0&d-16544-o=1&d-16544-p=1&p=off



http://guidance.nice.org.uk/TA10
































19


TA236 Acute coronary syndromes - ticagrelor Oct 2011

TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab Dec 2011

TA245 Venous thromboembolism - apixaban (hip and knee surgery) Jan 2012

TA248 Diabetes (type 2) - exenatide (prolonged release) Feb 2012

TA249 Atrial fibrillation - dabigatran etexilate Mar 2012

TA256 Atrial fibrillation (stroke prevention) - rivaroxaban May 2012

TA261 Venous thromboembolism (treatment & long term secondary prevention) - rivaroxaban July 2012

TA265 Bone metastases from solid tumours - denosumab Oct 2012

TA266 Cystic fibrosis - mannitol dry powder for inhalation Nov 2012

TA267 Chronic heart failure - ivabradine Nov 2012

TA274 Macular oedema (diabetic) - ranibizumab Feb 2013

TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban Feb 2013

TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin Mar 2013

TA283 Macular oedema (retinal vein occlusion) - ranibizumab May 2013

TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban Jun 2013

TA288 Type 2 diabetes - Dapagliflozin combination therapy Jun 2013

TA290 Overactive bladder - mirabegron Jun 2013

TA292 Bipolar disorder manic episodes (adolescents 13yrs and above) - aripiprazole July 2013

TA293 Thrombocytopenic purpura - eltrombopag July 2013

TA294 Macular degeneration (wet age-related) - aflibercept July 2013

TA297 Vitreomacular traction - ocriplasmin Oct 2013

TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab Nov 2013

TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant Nov 2013

TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection Feb 2014

TA315 Canagliflozin in combination therapy for treating type 2 diabetes Jun 2014

TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)

July 2014

TA318 Lubiprostone for treating chronic idiopathic constipation July 2014

TA323 Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)

Nov 2014

TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence Nov 2014

TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

Dec 2014

TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)

Feb 2015

TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Mar 2015

TA336 Empagliflozin in combination therapy for treating type 2 diabetes Mar 2015

TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy Mar 2015






















20


TA340 Ustekinumab for treating active psoriatic arthritis Jun 2015

TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and / or pulmonary embolism

Jun 2015

TA342 Vedolizumab for treating moderately to severely active ulcerative colitis Jun 2015

TA345 Naloxegol for treating opioid-induced constipation July 2015

TA346 Aflibercept for treating diabetic macular oedema July 2015

TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema July 2015

TA350 Secukinumab for treating moderate to severe plaque psoriasis July 2015

TA351 Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)

July 2015

TA352 Vedolizumab for moderately to severely active Crohn’s disease after prior therapy. (Hospital Trust)

Aug 2015

TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism

Aug 2015

TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation

Sep 2015

TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease. Oct 2015

TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears

Dec 2015

TA372 Apremilast for treating active psoriatic arthritis Dec 2015

TA375 Certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Jan 2016

TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Feb 2016

TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Feb 2016

TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Apr 2016




Documents

Primary Care Medicines Formulary - GP Ref · primary care and so not all may be specifically mentioned. Clinicians can and should prescribe medicines approved by NICE TAs where patients